DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Farletuzumab

Generic Name: Farletuzumab

Drug Type: Biotech

CAS Number: 896723-44-7

Unique Ingredient Identifier: 2O09BG0OWA

Overview

Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

Background

Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

Indication

Investigated for use/treatment in ovarian cancer.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Posted: 2022/11/14

Sponsor:Bristol-Myers Squibb

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Phase 2

Terminated

Posted: 2022/10/13

Sponsor:Bristol-Myers Squibb

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1

Recruiting

Posted: 2020/03/09

Sponsor:Eisai Inc.

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Phase 1

Completed

Posted: 2017/12/29

Sponsor:Eisai Inc.

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Phase 2

Completed

Posted: 2014/11/13

Sponsor:Eisai Inc.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Datopotamab Deruxtecan's Role in HR+/HER2- Breast Cancer Treatment: Sequencing and Safety Considerations

4 months ago

Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.

EU Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer

6 months ago

AbbVie's Elahere (mirvetuximab soravtansine) receives EU approval for folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer, marking a significant advancement in treatment options.

Targeted Therapies Show Promise in High-Grade Serous Ovarian Cancer Treatment

10 months ago

Traditional treatments for high-grade serous ovarian cancer, involving surgery and platinum-based chemotherapy, often lead to resistance, necessitating targeted therapies.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy